In beijing, the prices of stem cell injection vary according to a variety of factors. The cost of single injections ranges from $20,000 to $300,000, and some high-end or complex treatment projects may be more expensive。
Factors affecting the price of stem cell injections include, inter alia, cell sources, therapeutic purposes, technical complexity, injection doses and selected institutions. Based on the origin of the cells, self-contained stem cells are at a low risk of being immunely excluded and relatively low costs, usually ranging from $50,000 to $150,000 per injection; the cost of the amphibious stem cells, which come from donations from others and require rigorous formulation and anti-extrusion treatment, involving additional medical resources, is higher, with the cost of single injections usually ranging from $150,000 to $300,000。
The purpose of treatment is also an important factor influencing prices. The demand for cell activity and quantity is relatively low when applied to beauty resistance, skin improvement or sub-health regulation, with single costs ranging from $30,000 to $80,000. When used to treat complex diseases such as diseases of the nervous system (e. G. Parkinson's disease), cardiovascular diseases (e. G. Myocardial infarction), the cost increases significantly because of the need for high-dose cells, complex operations or multiple treatments, which may amount to between $100,000 and $250,000, or even higher。
In addition, the complexity of technology, injection doses and the level and regional levels of consumption of the selected institutions will have an impact on prices. Institutions using more advanced equipment and technology, or medical facilities located in front-line cities such as beijing, may be relatively expensive。
The beijing stem cell injection price table, which is risky because of the risk of stem cell injection, recommends the selection of qualified formal institutions and is conducted under the guidance of a professional physician. At the same time, it is important to be vigilant about the potential technical infeasibility or cost in some agencies, and to require agencies to provide complete cost lists and data on the success rate of treatment to ensure better treatment under safe conditions。
